VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will lead the advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering, and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA focuses on its BiTAC(R) bispecific T-cell engager platform, which aims to address solid tumors—a challenging area in oncology where many immunotherapies have limited efficacy. By combining Erkel’s expertise in T-cell engagers with VERAXA’s quality-by-design approach, the company hopes to accelerate the pipeline of bispecific antibodies and antibody-drug conjugates (ADCs). The full press release is available at https://nnw.fm/cR1RS.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company’s pipeline includes bispecific T-cell engagers, bispecific ADCs, and other innovative formats, all powered by transformative technologies. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
The announcement is significant for investors and the biotech industry as it signals VERAXA’s commitment to advancing its pipeline toward clinical trials. With Erkel’s background in leading immuno-oncology programs, the company may strengthen its position in the competitive bispecific antibody space. The latest news and updates regarding VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. These include factors set forth in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All parties undertake no duty to update this information unless required by law. The original release is available at www.newmediawire.com.
